More than 30 million Americans suffer from unrelieved chronic pain, such as nerve injury-induced neuropathic pain. Although a considerable amount is known about how chronic pain is induced, little is known about how acute pain naturally resolves. We hypothesize that disruption of local active pro-resolving processing will result in chronic pain. Current management of chronic pain mainly focuses on two types of drugs, ones that treat pain symptoms by blocking neurotransmission and those that modify disease progression by suppressing neuroinflammation. We now propose a novel approach for chronic pain therapy, using newly uncovered endogenous pro-resolving mediators. This approach focuses on novel endogenous lipid mediators namely resolvins and protectins that bring damaged system back to homeostasis by enhancing the phagocytic activity and clearance of local macrophages. Our recent results show that resolvins and protectins are very potent pro-resolving and anti-inflammatory agonists. Work in progress demonstrates that these novel endogenous mediators are also very effective, in nanogram dose range, in producing anti- hyperalgesic effects in animal models of inflammatory pain and neuropathic pain. We hypothesize that diminished production of resolvins and protectins after nerve injury will lead to the development of chronic pain. The overall goal of this application is to investigate whether and how resolvins and protectins can prevent and reverse neuropathic pain after nerve injury. We will employ multidisciplinary approaches, such as newly developed lipid mediator-lipidomics-informatics, animal behavior, electrophysiology, and several new biochemical systems including in vivo and in vitro assessment of macrophage phagocytosis to define the anti- hyperalgesic, pro-resolving, and anti-inflammatory roles of resolvins and protectins in animal models of neuropathic pain. These studies will involve formation of innovative partnership between Dr. Ji's pain research laboratory and Dr. Serhan's inflammation research group in the same department. In view of the results from work in progress, the results from the proposed studies will be transformative and have considerable impact on the entire pain community, from acute postoperative pain to chronic inflammatory pain and neuropathic pain.

Public Health Relevance

Although a considerable amount is known about how chronic pain is induced, little is known about how acute pain naturally resolves. We propose a novel approach for chronic pain therapy, using newly uncovered endogenous pro-resolving lipid mediators, namely resolvins and protectins. We will employ multidisciplinary approaches to define the anti-hyperalgesic, pro-resolving, and anti-inflammatory roles of resolvins and protectins in animal models of neuropathic pain. The results from the proposed studies will be transformative and have considerable impact on the entire pain community, from acute postoperative pain to chronic inflammatory and neuropathic pain.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS067686-05
Application #
8332858
Study Section
Special Emphasis Panel (ZRG1-BCMB-A (51))
Program Officer
Chen, Daofen
Project Start
2009-09-15
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$467,038
Indirect Cost
$100,694
Name
Duke University
Department
Anesthesiology
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Colas, Romain A; Shinohara, Masakazu; Dalli, Jesmond et al. (2014) Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 307:C39-54
Lee, Jun-Ho; Park, Chul-Kyu; Chen, Gang et al. (2014) A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. Cell 157:1393-404
Chen, Gang; Park, Chul-Kyu; Xie, Rou-Gang et al. (2014) Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice. Brain 137:2193-209
Park, Chul-Kyu; Xu, Zhen-Zhong; Berta, Temugin et al. (2014) Extracellular microRNAs activate nociceptor neurons to elicit pain via TLR7 and TRPA1. Neuron 82:47-54
Doyle, Jamie R; Krishnaji, Subrahmanian T; Zhu, Guangli et al. (2014) Development of a membrane-anchored chemerin receptor agonist as a novel modulator of allergic airway inflammation and neuropathic pain. J Biol Chem 289:13385-96
Berta, Temugin; Park, Chul-Kyu; Xu, Zhen-Zhong et al. (2014) Extracellular caspase-6 drives murine inflammatory pain via microglial TNF-? secretion. J Clin Invest 124:1173-86
Ji, Ru-Rong; Xu, Zhen-Zhong; Gao, Yong-Jing (2014) Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov 13:533-48
Liu, Xing-Jun; Zhang, Yanli; Liu, Tong et al. (2014) Nociceptive neurons regulate innate and adaptive immunity and neuropathic pain through MyD88 adapter. Cell Res 24:1374-7
Mirakaj, Valbona; Dalli, Jesmond; Granja, Tiago et al. (2014) Vagus nerve controls resolution and pro-resolving mediators of inflammation. J Exp Med 211:1037-48
Lu, Yan; Dong, Hailong; Gao, Yandong et al. (2013) A feed-forward spinal cord glycinergic neural circuit gates mechanical allodynia. J Clin Invest 123:4050-62

Showing the most recent 10 out of 40 publications